LLY

997.31

-0.83%↓

JNJ

227.5

-1.14%↓

ABBV

210.41

-0.16%↓

UNH

391.62

-2.08%↓

AZN

181.74

-1.93%↓

LLY

997.31

-0.83%↓

JNJ

227.5

-1.14%↓

ABBV

210.41

-0.16%↓

UNH

391.62

-2.08%↓

AZN

181.74

-1.93%↓

LLY

997.31

-0.83%↓

JNJ

227.5

-1.14%↓

ABBV

210.41

-0.16%↓

UNH

391.62

-2.08%↓

AZN

181.74

-1.93%↓

LLY

997.31

-0.83%↓

JNJ

227.5

-1.14%↓

ABBV

210.41

-0.16%↓

UNH

391.62

-2.08%↓

AZN

181.74

-1.93%↓

LLY

997.31

-0.83%↓

JNJ

227.5

-1.14%↓

ABBV

210.41

-0.16%↓

UNH

391.62

-2.08%↓

AZN

181.74

-1.93%↓

Home・Lista de Ações・CytoSorbents Corp

CytoSorbents Corp

Abrir

SetorSaúde

0.5 -3.85

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.5

Máximo

0.53

Indicadores-chave
By Trading Economics
Rendimento	-2.3M -5.5M
Vendas	-251K 9.2M
Margem de lucro	-59.526
Funcionários	129
EBITDA	-766K -3.7M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+31.58% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-2.7M 40M
Abertura anterior	4.35
Fecho anterior	0.5

Sentimento de Notícias

By Acuity

46%

54%

161 / 346 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

0.705 / 0.771 Suporte e Resistência

CytoSorbents Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de mai. de 2026, 22:44 UTC

Aquisições, Fusões, Aquisições de Empresas

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 de mai. de 2026, 22:27 UTC

Aquisições, Fusões, Aquisições de Empresas

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 de mai. de 2026, 22:12 UTC

Ganhos

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 de mai. de 2026, 21:52 UTC

Aquisições, Fusões, Aquisições de Empresas

LVMH to Sell Marc Jacobs

15 de mai. de 2026, 00:00 UTC

Ganhos

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 de mai. de 2026, 23:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 de mai. de 2026, 23:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 de mai. de 2026, 23:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 de mai. de 2026, 23:56 UTC

Conversa de Mercado

Gold Prices Rise on Strong Demand -- Market Talk

14 de mai. de 2026, 23:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 de mai. de 2026, 23:50 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

14 de mai. de 2026, 23:50 UTC

Conversa de Mercado

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 de mai. de 2026, 23:47 UTC

Ganhos

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 de mai. de 2026, 23:47 UTC

Ganhos

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 de mai. de 2026, 23:46 UTC

Ganhos

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 de mai. de 2026, 23:46 UTC

Ganhos

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 de mai. de 2026, 23:28 UTC

Conversa de Mercado

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 de mai. de 2026, 23:00 UTC

Conversa de Mercado

Australia's One Nation Party Leads In The Polls -- Market Talk

14 de mai. de 2026, 22:46 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

14 de mai. de 2026, 22:46 UTC

Conversa de Mercado

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 de mai. de 2026, 22:46 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 de mai. de 2026, 22:35 UTC

Conversa de Mercado

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 de mai. de 2026, 22:11 UTC

Aquisições, Fusões, Aquisições de Empresas

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 de mai. de 2026, 22:06 UTC

Conversa de Mercado

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 de mai. de 2026, 22:04 UTC

Ganhos

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 de mai. de 2026, 22:04 UTC

Ganhos

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 de mai. de 2026, 22:04 UTC

Ganhos

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 de mai. de 2026, 22:00 UTC

Ganhos

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 de mai. de 2026, 21:55 UTC

Ganhos

Nu Holdings 1Q EPS 18c >NU

14 de mai. de 2026, 21:55 UTC

Ganhos

Nu Holdings 1Q Rev $4.97B >NU

Comparação entre Pares

Variação de preço

CytoSorbents Corp Previsão

Preço-alvo

By TipRanks

31.58% parte superior

Previsão para 12 meses

Média 0.75 USD 31.58%

Máximo 0.75 USD

Mínimo 0.75 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para CytoSorbents Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para CytoSorbents Corp - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

0.705 / 0.771Suporte e Resistência

All events are bearish.

Sentimento

By Acuity

161 / 346 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.